Fluorinated Cyclic Dinucleotide Synthesis via Enzyme Mediator
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current synthetic methods for fluorinated thiophosphoro cyclic dinucleotides are inefficient, requiring multiple steps and resulting in poor yields and the need for labor-intensive HPLC purification, with challenges in controlling stereogenic chiral centers and achieving high diastereoselectivity.
Innovation Solution
A two-step synthetic process using evolved cGAS enzyme and kinase enzymes to prepare fluorinated cyclic dinucleotides from thio-monophosphates, with high diastereoselectivity and direct isolatability via pH-swing crystallization, starting from readily available materials like guanosine or xylose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional multi-step synthetic methods are used to prepare fluorinated thiophosphoro cyclic dinucleotides, then complete chemical transformation can be achieved, but the synthesis requires over eight steps with poor yields and labor-intensive HPLC purification
Solution Approach 1:
The patent uses engineered cGAS enzyme as a biological intermediary to catalyze the formation of cyclic dinucleotides from thio-monophosphate substrates. This enzyme mediator enables the reaction to proceed through a biocatalytic pathway that is more efficient and selective than traditional chemical synthesis methods, reducing the number of steps required while improving yield and eliminating the need for complex HPLC purification
Solution Approach 2:
The patent employs engineered cGAS enzymes with modified amino acid sequences that have been optimized for enhanced catalytic activity and stereoselectivity. By changing the biochemical parameters of the enzyme (through directed evolution and rational design), the reaction achieves high diastereoselectivity and produces the desired cyclic dinucleotide product with no detectable diastereomeric impurities, thereby simplifying the overall synthesis process
2Manufacturing precision
If traditional methods are used to control stereogenic chiral centers, then chemical synthesis can proceed, but high diastereoselectivity is difficult to achieve and labor-intensive HPLC purification is required
Solution Approach 1:
The engineered cGAS enzyme acts as a chiral mediator that controls the stereochemistry of the reaction. The enzyme's active site provides a chiral environment that directs the formation of specific diastereomers at the stereogenic phosphorus centers, achieving high diastereoselectivity without requiring complex chiral auxiliaries or multiple purification steps
Solution Approach 2:
The patent replaces the mechanical/chemical purification system (HPLC) with a biocatalytic system that inherently produces high diastereoselectivity. The engineered cGAS enzyme substitutes for complex chemical reagents and purification equipment by providing stereoselective catalysis that directly yields the desired product with no detectable diastereomeric impurities, simplifying the operation significantly
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process provides a more efficient route to fluorinated thiophosphoro cyclic dinucleotides with no detectable diastereomeric impurities, offering a significant improvement over previous methods by reducing the number of steps and simplifying purification.
Implementation Method 1
A two-step synthetic process using evolved cGAS enzyme and kinase enzymes to prepare fluorinated cyclic dinucleotides from thio-monophosphates
Implementation Method 2
direct isolatability via pH-swing crystallization
Data Source
AI summary
The present invention relates to efficient processes useful in the preparation of fluorinated cyclic dinucleosides, such as [P(R)]-2′-deoxy-2′-fluoro-5′-O—[(R)-hydroxymercaptophosphinyl]-P-thio-β-D-arabino-adenylyl-(3′→5′)-3′-deoxy-3′-fluoroguanosine cyclic nucleotide, which is also known as (2R,5R,7R,8S,10R,12aR,14R,15S,15aR,16R)-7-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-14-(6-amino-9H-purin-9-yl)-15,16-difluoro-2, 10-bis(sulfanyl)octahydro-2H,10H, 12H-2λ5,10λ5-5,8-methanofuro[3,2-1][1, 3,6,9,11,2,10]pentaoxadiphosphacyclotetradecine-2,10-dione. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.